Listen to the news

The race for time continues between pharmaceutical companies, doctors, scientists and the Corona virus, in an attempt to overcome this virus that paralyzed the world for several months and still controls many areas of life.

In a new scientific precedent, AstraZeneca announced today, Friday, that an antibody treatment based on its development achieved the primary goal in preventing Covid-19 disease in an advanced study, which puts the British pharmaceutical company on the right track to provide a possible alternative to vaccines for those suffering from Weakened immune system.

Reduced risk of infection by 77%
She said that the combination of two types of antibodies, which was initially discovered by the Vanderbilt University Medical Center, reduced the risk of contracting Covid-19 with symptoms by 77 percent.

She also added that more than 75 percent of the participants were suffering from chronic diseases, some of which are linked to a weak immune response to vaccines.

It is noteworthy that these results represent a change in the fortunes of the company, which said last June that a smaller study during the late stages failed to provide evidence that the mixture of antibodies protects those who have been in contact with an infected person from infection with the disease.